Fecal matter transplant
A fecal matter transplant or fecal microbiota transplant (FMT) is a therapy that involves the transfer of fecal waste from a healthy donor to the colon of a patient. It's most common use is in the treatment of recurrent clostridium difficile (c.diff) infections. Interest in fecal matter transplants has grown in those experiencing chronic gastrointestinal problems, including chronic fatigue syndrome.
Methods[edit | edit source]
Fecal matter from a person with healthy gut flora is mixed with saline, strained, inserted into the recipient patient with via a colonoscopy, endoscopy, sigmoidoscopy, or enema in order to recolonize the ill person's bowels. It is recommended that the donor be someone close to the patient, with the first choice being a spouse or significant other, but other close friends, relatives, or a “universal donor” source may be warranted. The physician should ensure that the “universal donor” source employs rigorous screening and testing standards. Testing includes screening the donors’ blood for diseases such as HIV and hepatitis and testing their stool for bacterial pathogens, giardia and cryptosporidium, parasites, and C. difficile.
Risk[edit | edit source]
Multi-drug resistant organisms[edit | edit source]
The FDA reported two cases of bacterial infections with multi-drug resistant organisms (MDROs) that occurred due to use of investigational FMT. In both cases, the FMT was prepared from stool obtained from the same donor, and the recipients became infected with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E.coli), which was later found to be present in donor stool. One of the recipients died. As a result of these cases, the FDA has determined that donor screening must include questions that address risk factors for MDROs and donor stools must be tested for MDROs.
Availability[edit | edit source]
United States[edit | edit source]
FMT is regulated by the U.S. Food and Drug Administration (FDA), which has not approved it for any use. The FDA has classified human stool as a biological agent and determined that its use in fecal matter transplantation (FMT) therapy and other research should be regulated to ensure patient safety. In order for a physician or researcher to use FMT in a clinical trial or to treat any condition other than reoccurring, antibiotic-resistant clostridium difficile infections, an investigational new drug (IND) permit is required.
United Kingdom[edit | edit source]
Australia[edit | edit source]
Australia has some of the most active FMT clinics, such as the Centre for Digestive Diseases in Sydney, under the direction of Thomas J. Borody, MD, PhD. Dr Borody has conducted many FMT studies over the past 30 years on FMT, including studies assessing efficacy for chronic fatigue syndrome, although criticism regarding patient selection and follow-up have caused doubt on the study results. (Critique can be found in a section below.) Additionally Dr Paul Froomes, Melbourne, performs FMT.
Norway[edit | edit source]
A randomized, placebo-controlled trial called "The Comeback" study is currently underway at the University Hospital of North Norway. Eighty ME/CFS patients will be followed up for 12 months after receiving either fecal microbiota transplantation (FMT) or a placebo. The trial will take many years to complete. Final results are expected in 2023.
Home experimentation[edit | edit source]
The medical cautions and strict FDA regulation hasn't stopped people, especially those with GI illnesses, such as ulcerative colitis or irritable bowel syndrome, from experimenting on their own with FMT. Recipes for do-it-yourself FMT are abundant online, including Dr. Sarah Myhill's protocol, Probiotic Therapy Home Infusion Protocol.
Critique of Borody study using FMT for chronic fatigue syndrome[edit | edit source]
A 2012 study by Borody, at el, using a variety of antibiotics followed by one to three fecal matter transplants (and in six patients an oral course of cultured bacteria), reported a 70% rate of improvement of sleep and "lethargy/fatigue" symptoms in Fukuda CFS patients recruited from a clinic for digestive disorders. The authors reported a 58% success rate at long term followup 15-20 years post-treatment, but only 12 patients (out of the original 60) were contacted at that point. Accordingly, the long-term followup results would not have been statistically significant.
That study also neglected to use any objective outcome measurements, a control group was not included, and the symptoms used to determine a successful outcome regarding "CFS symptoms" did not account for physical limitations or many other fundamental ME/CFS symptoms. It is not clear how many symptoms were measured before and after treatment, hence it cannot be determined if any results were statistically significant. Furthermore, all patients were recruited from a clinic for digestive disorders, which would suggest that they were not typical ME/CFS patients. The recruitment criteria did not require that patients have the symptom of post-exertional malaise, hence the results may not be applicable to ME/CFS patients meeting more stringent criteria.
There was no study protocol published, and there is no explanation provided for the results first being published as a full paper fifteen years after the initial treatments took place. A conference poster abstract from 1995 indicates that other symptoms were tested at an earlier followup, but those symptoms are not reported or discussed in the 2012 long-term followup, which may indicate that the treatment was less successful than reported. The poster abstract does not appear to have been published, and the full long-term followup was published in an obscure online journal with no apparent peer review process.
This study has not been replicated, and no other studies for FMT and ME/CFS have been conducted. Accordingly, the existing evidence base in favor of this therapy is very weak.
Research studies[edit | edit source]
- 2012, The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy
- 2013, High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients
- 2016, Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders
- 2019, A retrospective outcome study of 42 patients with Chronic Fatigue Syndrome, 30 of whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Designer Shit – a documentary about FMT scheduled for release sometime in 2019
- Home Infusion Protocol published by Sarah Myhill
- Infectious Diseases Society of America Information about FDA regulations re: FMT
- The Fecal Transplant Foundation
- 24 Aug 2019, The First ME/CFS Fecal Transplant Study Suggests the Treatment Holds Promise by Cort Johnson for Simmaron Research
References[edit | edit source]
- Bakken, Johan S.; Borody, Thomas; Brandt, Lawrence J.; Brill, Joel V.; Demarco, Daniel C.; Franzos, Marc Alaric; Kelly, Colleen; Khoruts, Alexander; Louie, Thomas (Dec 1, 2011). "Treating Clostridium difficile Infection With Fecal Microbiota Transplantation". Clinical Gastroenterology and Hepatology. 9 (12): 1044–1049. doi:10.1016/j.cgh.2011.08.014. ISSN 1542-3565.
- "What is FMT? – The Fecal Transplant Foundation". Retrieved Jun 11, 2019.
- "Fecal Microbiota Transplantation". www.idsociety.org. Retrieved Jun 11, 2019.
- "Fecal transplants: the scoop on therapeutic poop". Scienceline. Nov 15, 2011. Retrieved Jun 11, 2019.
- "Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms". U.S. Food & Drug Administration. Jun 13, 2019. Retrieved Jun 15, 2019.
- "FDA In Brief: FDA warns about potential risk of serious infections caused by multi-drug resistant organisms related to the investigational use of Fecal Microbiota for Transplantation". U.S. Food & Drug Administration. Jun 13, 2019. Retrieved Jun 15, 2019.
- "Fecal Microbiota Transplantation". www.idsociety.org. Retrieved Jun 11, 2019.
- "Gut Flora Transplants". Taymount Clinic. Retrieved Jun 11, 2019.
- "The Centre for Digestive Diseases – The centre of excellence for gastroenerology". Retrieved Jun 11, 2019.
- "Home". Dr Paul Froomes - Consultant Gastroenterologist | Melbourne. Retrieved Jun 11, 2019.
- "The Comeback Study - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved Jun 11, 2019.
- "Probiotic Therapy Home Infusion Protocol" (PDF). Retrieved Jun 11, 2019.
- Borody, Thomas J; Nowak, Anna; Finlayson, Sarah (Dec 2012). "The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy". Journal of the Australasian College of Nutritional and Environmental Medicine. 31 (3): 3–8.
- Borody, TJ (1995). "Bacteriotherapy for Chronic Fatigue Syndrome – A long-term follow-up study". Proceedings of ACMA Complementary Medicine Sydney 1995.
- Frémont, Marc; Coomans, Danny; Massart, Sebastien; De Meirleir, Kenny (Aug 2013). "High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients". Anaerobe. 22: 50–56. doi:10.1016/j.anaerobe.2013.06.002.
- Evrensel, Alper; Ceylan, Mehmet Emin (Aug 31, 2016). "Fecal Microbiota Transplantation and Its Usage in Neuropsychiatric Disorders". Clinical Psychopharmacology and Neuroscience. 14 (3): 231–237. doi:10.9758/cpn.2016.14.3.231. ISSN 1738-1088.
- Kenyon, J.N.; Coe, Shelly; Izadi, Hooshang (Aug 2019). "A retrospective outcome study of 42 patients with Chronic Fatigue Syndrome, 30 of whom had Irritable Bowel Syndrome. Half were treated with oral approaches, and half were treated with Faecal Microbiome Transplantation". Human Microbiome Journal. 13: 100061. doi:10.1016/j.humic.2019.100061.
Randomized controlled trial (RCT) - A trial in which participants are randomly assigned to two groups, with one group receiving the treatment being studied and a control or comparison group receiving a sham treatment, placebo, or comparison treatment.
Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.